ATAI

AtaiBeckley Inc

Apr 08 • 04:00PM ET

3.76

-0.03 -0.79 %

Healthcare • Biotechnology • USA • NASD

Apr 08, 6:05 AMAtaiBeckley peer-reviewed Phase 2a data show BPL-003 induces rapid, durable antidepressant responses in treatment-resistant depression patients on SSRIs

Peers: CMPS DFTX GHRS HELP RLMD SLS ANIX RGLS VNDA

| Held by: ARKG IBB SCHA PSIL ITOT NUSC SCHB BBSC ONEQ ISCG

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.31	Insider Own	20.22%	Shs Outstand	363.28M	Perf Week	6.21%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-0.48	Insider Trans	0.00%	Shs Float	290.98M	Perf Month	-3.34%
Enterprise Value	1.12B	PEG	-	EPS next Q	-0.11	Inst Own	14.03%	Short Float	5.97%	Perf Quarter	-6.00%
Income	-660.05M	P/S	335.32	EPS this Y	83.79%	Inst Trans	3.93%	Short Ratio	3.80	Perf Half Y	-31.26%
Sales	4.09M	P/B	6.16	EPS next Y	-0.81%	ROA	-	Short Interest	17.37M	Perf YTD	-8.07%
Book/sh	0.61	P/C	5.36	EPS next 5Y	45.73%	ROE	-	52W High	6.75 -44.30%	Perf Year	210.74%
Cash/sh	0.70	P/FCF	-	EPS past 3/5Y	-43.86% 36.94%	ROIC	-295.09%	52W Low	1.15 226.96%	Perf 3Y	111.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	159.87% -	Gross Margin	-	Volatility	5.71% 6.10%	Perf 5Y	-
Dividend TTM	-	EV/Sales	273.25	EPS Y/Y TTM	-186.61%	Oper. Margin	-2835.93%	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.74	Sales Y/Y TTM	-	Profit Margin	-16142.02%	RSI (14)	53.11	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.74	EPS Q/Q	-959.66%	SMA20	3.70%	Beta	1.58	Target Price	13.33
Payout	-	Debt/Eq	0.01	Sales Q/Q	2565.00%	SMA50	0.64%	Rel Volume	1.12	Prev Close	3.79
Employees	99	LT Debt/Eq	0.01	Earnings	Mar 06 BMO	SMA200	-8.67%	Avg Volume	4.57M	Price	3.76
IPO	Jun 18, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1558.68% 255.33%	Trades		Volume	5,090,577	Change	-0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	Deutsche Bank	Buy	$12
Jan-20-26	Initiated	Guggenheim	Buy	$11
Oct-13-25	Initiated	Needham	Buy	$12
Jul-29-25	Initiated	Oppenheimer	Outperform	$14
Nov-18-24	Reiterated	H.C. Wainwright	Buy	$15 → $10
Apr-03-24	Upgrade	Maxim Group	Hold → Buy	$6
Nov-01-22	Initiated	Loop Capital	Buy	$18
Nov-30-21	Initiated	Maxim Group	Buy	$25
Nov-11-21	Initiated	ROTH Capital	Buy	$32
Oct-18-21	Initiated	H.C. Wainwright	Buy	$40
Sep-01-21	Initiated	Jefferies	Buy	$27
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform	$19
Jul-13-21	Initiated	Credit Suisse	Outperform	$25
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Citigroup	Buy	$26
Jul-13-21	Initiated	Cantor Fitzgerald	Buy	$45
Jul-13-21	Initiated	Canaccord Genuity	Buy	$28
Jul-13-21	Initiated	Berenberg	Buy	$35
Jul-08-21	Initiated	Aegis Capital	Buy	$26

Show Previous Ratings

Apr-08-26 08:40AM	AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003 (Proactive)
06:00AM	AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs (GlobeNewswire)
Mar-29-26 10:25AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-27-26 11:25AM	AtaiBeckley awarded Buy rating in initial coverage from Deutsche Bank analysts (Proactive) -5.37%
Mar-24-26 08:36AM	AtaiBeckley added to major US indices, increasing reach among passive investors (Proactive)
06:00AM	Loading…
06:00AM	AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst (GlobeNewswire)
Mar-17-26 09:09AM	AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003 (Proactive)
06:00AM	BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation (GlobeNewswire)
Mar-10-26 10:45AM	AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day (Proactive) +6.43%
06:00AM	BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day (GlobeNewswire)
Mar-09-26 10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire) +14.75%
Mar-08-26 12:57PM	AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 (Insider Monkey)
11:17AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
08:41AM	AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial (Proactive)
07:00AM	Loading…
07:00AM	AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update (GlobeNewswire)
Mar-05-26 10:38AM	Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints (Benzinga)
Mar-04-26 11:40AM	AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting (Insider Monkey)
05:39AM	AtaiBeckley Inc (ATAI)'s Drug Candidate EMP-01 Shows Positive Results in Key Study (Insider Monkey)
Mar-03-26 08:07AM	AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing (Proactive)
07:00AM	AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression (GlobeNewswire)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
06:58AM	Cathie Wood "Buys the Dip" in Baidu Stock -- Should You? (GuruFocus.com)
Feb-26-26 03:49PM	Dow Jones back level but Nasdaq in the red thanks to Nvidia (Proactive) -14.06%
09:49AM	AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data (Benzinga)
09:47AM	AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial (Proactive)
07:00AM	AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder (GlobeNewswire)
Feb-20-26 07:00AM	AtaiBeckley To Host Virtual Investor Day on March 6, 2026 (GlobeNewswire)
Feb-19-26 03:30PM	Dow Jones leads Wall Street lower, US-Iran fears drive oil higher (Proactive)
08:21AM	AtaiBeckley names Michael Faerm as finance chief (Proactive)
07:00AM	Loading…
07:00AM	AtaiBeckley Appoints Michael Faerm as Chief Financial Officer (GlobeNewswire)
Feb-17-26 07:00AM	AtaiBeckley To Participate in Upcoming Investor Conferences (GlobeNewswire) +6.44%
Feb-15-26 04:08AM	Wall Street Bullish on AtaiBeckley (ATAI), Here's Why (Insider Monkey)
Feb-13-26 11:44AM	Here's What Analysts Are Saying About AtaiBeckley Inc. (ATAI) (Insider Monkey)
07:13AM	AtaiBeckley Inc. (ATAI) Gains Momentum With Promising BPL-003 Data and Strong Analyst Support (Insider Monkey)
Jan-30-26 02:58PM	Guggenheim Initiates Buy Rating for AtaiBeckley (ATAI) With $11 PT, Cites Leadership in Psychiatry (Insider Monkey)
Jan-29-26 01:48PM	H.C. Wainwright Remains Bullish on AtaiBeckley Inc. (ATAI) (Insider Monkey)
Jan-19-26 11:28AM	High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (MarketBeat)
Jan-18-26 12:30PM	Atai Beckley N.V. (ATAI) Achieves Significant Milestone on Pipeline Development and Corporate Foundation (Insider Monkey)
Jan-16-26 07:00AM	AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation (GlobeNewswire)
Jan-14-26 02:13PM	Atai Beckley N.V. (ATAI) is a Buy on Mental Therapeutics Opportunities (Insider Monkey)
Jan-13-26 04:01AM	New Strong Sell Stocks for Jan. 13 (Zacks)
Jan-09-26 07:17AM	Atai Beckley CEO says entering 2026 with meaningful momentum (TipRanks) -5.54%
Jan-08-26 07:00AM	AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-26 04:51PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-30-25 06:55PM	AtaiBeckley Completes Redomiciliation to the United States (GlobeNewswire)
Dec-27-25 07:43AM	JonesTrading Highlights Differentiated Pipeline at Atai Beckley N.V. (ATAI) (Insider Monkey)
Dec-25-25 08:30AM	The 1 Riskiest Investment That Paid Off in 2025 (Barchart)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
07:00AM	AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat) +8.59%
Dec-18-25 01:14AM	Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation (Insider Monkey)
Dec-15-25 08:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-11-25 07:00AM	AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio (GlobeNewswire)
Nov-25-25 08:39AM	H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion (Insider Monkey)
Nov-19-25 07:32PM	Enhanced Fortifies Executive Leadership Team & Board of Directors (PR Newswire)
Nov-18-25 06:16AM	Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato (Insider Monkey)
Nov-13-25 09:00AM	AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-12-25 07:00AM	AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-25 07:00AM	AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression (GlobeNewswire)
Nov-05-25 07:00AM	atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies (GlobeNewswire) -15.15%
Oct-20-25 05:29PM	atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares (GlobeNewswire) -8.57%
12:00PM	atai Life Sciences (ATAI) Upgraded to Buy: Here's Why (Zacks)
Oct-17-25 08:06AM	Why Atai Life Sciences Stock Was So Lively This Week (Motley Fool) +17.70%
Oct-16-25 10:31PM	atai Life Sciences Announces Pricing of Public Offering of Common Shares (GlobeNewswire) -8.05%
04:12PM	atai Life Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
04:10PM	atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression (GlobeNewswire)
Sep-24-25 07:09AM	atai and Beckleys psychedelic advances to pivotal TRD trial (Clinical Trials Arena)
Sep-23-25 07:21PM	Atai Life Sciences N.V. (ATAI) Advances Psychedelic Therapies for Mental Health, Drawing Investor Spotlight (Insider Monkey) +14.96%
05:51PM	Why Atai Life Sciences Stock Crushed It on Tuesday (Motley Fool)
02:50PM	Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients (Benzinga)
07:00AM	atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression (GlobeNewswire)
Sep-21-25 09:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-20-25 02:43AM	H.C. Wainwright Affirms 'Buy' Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects (Insider Monkey)
Sep-19-25 09:40AM	Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? (Zacks)
08:10AM	Atai Life Sciences awarded grant worth up to $11.4M from NIH (TipRanks)
Sep-18-25 08:00AM	atai Life Sciences Awarded Grant from the National Institutes of Health (GlobeNewswire)
Sep-11-25 12:00PM	atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-03-25 09:40AM	Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year? (Zacks)
Sep-02-25 03:49AM	Atai Life Sciences N.V. (ATAI)'s BPL-003 Achieves Robust Phase 2b Success in Treatment-Resistant Depression (Insider Monkey)
Aug-28-25 04:05PM	atai Life Sciences to Participate in September Investor Conferences (GlobeNewswire)
Aug-25-25 11:56PM	H.C. Wainwright Reiterates a Buy Rating on Atai Life Sciences (ATAI) (Insider Monkey)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-20-25 12:21AM	ATAI Life Sciences (ATAI) Rated as 'Outperform' at Oppenheimer on Psychedelic Prospects (Insider Monkey)
Aug-18-25 06:07PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
09:55AM	Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-14-25 07:00AM	atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates (GlobeNewswire)
Aug-04-25 10:01AM	Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT (Insider Monkey)
Jul-31-25 11:40PM	H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 (Insider Monkey) +18.16%
Jul-28-25 08:55AM	ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News (GuruFocus.com) -6.72%
06:17AM	Atai backs away from schizophrenia drug after trial failure (BioPharma Dive)
05:51AM	Recognifys Phase IIb trial of schizophrenia therapy fails to meet primary goal (Clinical Trials Arena)
Jul-25-25 04:05PM	Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia (GlobeNewswire)
Jul-21-25 12:00PM	atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why (Zacks) +9.29%
Jul-11-25 07:13PM	Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target (Insider Monkey)
09:40AM	Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-09-25 10:36AM	Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)'s Price Target To $12, Maintains Buy Rating (Insider Monkey)
07:19AM	Atai Life Sciences, Beckley Psytech Announce Positive Topline Results for BPL-003 (Insider Monkey)
Jul-06-25 05:30AM	The MAHA Movement Loves Psychedelics. Should Wall Street? (The Wall Street Journal)
Jul-01-25 03:06PM	A Promising Depression Drug Works. Psychedelics Are Back. (Barrons.com) +23.74%

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KEVIN JAMES CRAIG	Officer	Mar 20 '26	Proposed Sale	3.57	100,000	357,000		Mar 20 04:41 PM
Feilding-Mellen Cosmo	Director	Feb 26 '26	Proposed Sale	4.00	750,000	3,000,000		Feb 26 04:11 PM
Apeiron Investment Group Ltd.	10% Owner	Aug 14 '25	Buy	2.19	8,675,799	19,000,000	51,045,214	Aug 18 06:00 PM
SAHIL KIRPEKAR	Officer	Jul 02 '25	Proposed Sale	2.81	83,332	233,830		Jul 02 04:13 PM
SAHIL KIRPEKAR	Officer	Jul 01 '25	Proposed Sale	2.77	106,093	294,381		Jul 01 04:16 PM
SAHIL KIRPEKAR	Officer	Jun 04 '25	Proposed Sale	2.48	80,000	198,408		Jun 04 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATAI

AtaiBeckley Inc

Upgrade your Finviz experience